Celltrion, Inc., today announced that STEQEYMA® (ustekinumab-stba), a biosimilar to STELARA® (ustekinumab) has been added to ...

JERSEY CITY, N.J., March 27, 2025 /PRNewswire/ -- Celltrion, Inc., today announced that STEQEYMA ® (ustekinumab-stba), a biosimilar to STELARA ® (ustekinumab) has been added to the Costco Member ...

Samsung Biologics, Celltrion Lead Pharmaceutical Industry with Average Salary Over 100 Million Won Biopharmaceutical giants ...

Steqeyma is indicated for the treatment of plaque psoriasis and psoriatic arthritis in adult and pediatric patients, as well ...

Suh Jin-seok targets 700 billion won for Jimpenetra as shipments double Suh Jin-seok anticipates substantial growth for ...

The FDA has approved two new denosumab biosimilars that are interchangeable with the reference medications Prolia and Xgeva, ...

On March 26, 2025, the FDA approved Fresenius Kabi’s denosumab biosimilars, CONEXXENCE® (denosumab-bnht) and BOMYNTRA® (denosumab-bnht), ...

Celltrion, a major South Korean biopharmaceutical firm, on Tuesday said it aims to achieve 5 trillion won ($3.46 billion) in s ...

Korean pharmaceutical giant Celltrion on Tuesday pledged to achieve an annual growth rate of 30 percent and a return on equity of at least 7 percent by 2027, as part of its long-term initiative ...